Eli Lilly disclosed Q1 2026 revenue of $19.8 billion via SEC 8-K filing, representing 56% growth compared to the prior-year quarter.
Q1 2026 Results at a Glance
Q1 2026 revenue reached $19.8 billion, up 56% from $12.7 billion in the prior-year quarter. Volume growth of 65% was partially offset by a 13% decline in realized net pricing for Mounjaro and Zepbound. GAAP net income surged 168% to $7.4 billion versus the year-ago period.
- Revenue: $19.8 billion, +56% YoY
- EPS (GAAP): $8.26, up 170% from $3.06
- EPS (Non-GAAP): $8.55, up 156% from $3.34
- Net Income (GAAP): $7.4 billion, +168% YoY
- Net Income (Non-GAAP): $7.7 billion, +155% YoY
- Gross Margin (GAAP): $16.2 billion, 81.9% of revenue
- R&D Expense: $3.5 billion, +28% YoY
2026 Full-Year Guidance
Eli Lilly raised full-year 2026 revenue guidance to $82-85 billion, up $2.0 billion from prior guidance. Non-GAAP EPS guidance for the year is $35.50-37.00. CEO David Ricks stated: "2026 is off to a strong start. We achieved 56% revenue growth in Q1 and raised our annual revenue guidance by $2.0 billion."
Market Reaction
Stock price rose following the earnings announcement. Barron's reported that Mounjaro and Zepbound revenue surges significantly exceeded market expectations. Reuters noted that the GLP-1 class of therapeutics drove growth and full-year profit outlook was revised upward. Specific share price movement figures were not disclosed.
Business Segment Performance
- Mounjaro (diabetes): $8.66 billion, up 125% from $3.84 billion YoY
- Zepbound (obesity): Partial disclosure in filing
- U.S. Revenue: $12.1 billion, +43% YoY
- International Revenue: $7.7 billion, +81% YoY
- Core Product Portfolio (Mounjaro, Zepbound, others): $13.4 billion
- Immunology, Oncology, and Neuroscience Core Products: +160% YoY
This article was auto-generated from SEC 8-K filings and external news sources, designed for rapid dissemination of key data immediately post-announcement. Investors should review official company disclosures before making trading decisions.
